Q1 EPS Forecast for Anixa Biosciences Boosted by Analyst

Anixa Biosciences, Inc. (NASDAQ:ANIX) – HC Wainwright increased their Q1 2025 earnings per share estimates for Anixa Biosciences in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.41) EPS.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Wednesday, January 22nd.

Anixa Biosciences Stock Up 10.5 %

Shares of NASDAQ:ANIX opened at $3.17 on Friday. The business’s 50-day moving average is $2.71 and its 200 day moving average is $3.05. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Focus Partners Wealth acquired a new stake in Anixa Biosciences in the fourth quarter valued at approximately $162,000. Jane Street Group LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter valued at approximately $67,000. International Assets Investment Management LLC grew its stake in Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. Prosperity Wealth Management Inc. purchased a new stake in Anixa Biosciences in the 4th quarter worth $54,000. Finally, Westside Investment Management Inc. raised its position in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the period. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Insiders Place Their Bets

In other news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the business’s stock in a transaction on Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the acquisition, the director now owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Amit Kumar bought 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 75,289 shares of company stock valued at $177,021. Company insiders own 25.30% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.